Oct 18, 2017
Shareholder Update October 2017

In this issue:
>> DEP® docetaxel achieves positive phase 1 results and commences phase 2
>> AZ presents first DEP® candidate AZD0466 – a Bcl2/xL inhibitor
>> Successful VivaGel® BV phase 3 results
>> Update on other internal DEP® candidates
>> Grant awarded to Starpharma-Monash
>> Starpharma and Peter Mac Cancer Centre awarded grant
>> FY17 Financial results; >$60M cash at 30 June
>> Annual Report and Annual General Meeting
>> Starpharma News & Events
Download: Shareholder Update October 2017 (pdf file, 1.3mb)
This contains certain forward-looking statements.